Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Inflammatory Breast Neoplasms 1Glioblastoma 1COVID-19 1Adenocarcinoma of Lung 1

Interventions

Cytarabine 167fludarabine phosphate 102Cyclophosphamide 97Azacitidine 92Whole-Body Irradiation 78fludarabine 77Mycophenolic Acid 71Busulfan 68Tacrolimus 59Peripheral Blood Stem Cell Transplantation 55Decitabine 55Granulocyte Colony-Stimulating Factor 49Filgrastim 44Daunorubicin 44Cyclosporine 42Methotrexate 41Melphalan 41Etoposide 41Clofarabine 41Idarubicin 39Mitoxantrone 34Antilymphocyte Serum 34venetoclax 32thymoglobulin 23Thiotepa 23Stem Cell Transplantation 21Injections 16Gemtuzumab 16CPX-351 16Sirolimus 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid, Acute × bemcentinib × Clear all
NCT06469138 2025-01-29

8479217

BerGenBio ASA

Phase 1 Completed
6 enrolled 17 charts
CNSDermatologicGastrointestinalMyeloidOther hematologic neoplasmOther solid neoplasmThoracic

Mesothelioma, Malignant, COVID-19, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Myelodysplastic Syndromes, Pancreatic Neoplasms, Leukemia, Myeloid, Acute

NCT02488408 2024-12-19

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

BerGenBio ASA

Phase 1/2 Completed
122 enrolled 29 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡